Plasma reaches $2.5b market cap as markets speculate on Tether connection
Stablecoin blockchain Plasma token quickly rose to $2.5 billion in market cap after the Tether partnership.
- Stablecoin-focused blockchain Plasma (XPL) token rose to $2.5 billion hours after launch
- The network specializes in fast and low-cost stablecoin transactions
- Plasma made a partnership with Tether and had Bitfinex as a major investor
Stablecoin infrastructure is capturing significant attention among traders. On Friday, September 26, Plasma’s XPL token reached $2.5 billion in market cap, just a day after launch, breaking into the top 50 largest coins. Currently trading at $1.19, the stablecoin-focused XPL is benefiting from the hype around stablecoins and its association with Tether.
Plasma positions itself as a “money chain,” enabling sub-second finality and low costs for stablecoin transfers, a growing use case in crypto. At the same time, the project has already attracted billions in stablecoin liquidity through partnerships with projects like Aave, Ethena, Fluid, and Euler. What is more, the network reached $3.89 billion in stablecoin market cap just one day after launch .
Still, the low fees are also a source of risk for the token, especially given its high valuation. Notably, on its first day of trading, total network fees were just $4,200, making a $2 billion valuation hard to justify on economics alone.
Markets speculate about Plasma’s links to Tether
A likely factor in XPL’s quick growth is speculation about its potential links to Tether, the world’s largest stablecoin issuer. For this reason, Tether, which did not launch its own stablecoin-focused blockchain, may come to rely on Plasma for cheap and fast stablecoin transfers.
For one, Tether entered a partnership with Plasma, providing it with $2 billion in USD₮ liquidity. Tether also integrated its omnichain stablecoin XAU₮ with Plasma, making it available for trading at launch time.
What is more, Tether’s owner, Bitfinex, was a major backer for Plasma, contributing $24 million. Both of these factors suggest that Plasma is aligned with Tether’s interest.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
